Kiattipong / Shutterstock.com
LSIPR provides a look behind the scenes of Shire Pharmaceuticals, the Irish company valued at £46 billion by its acquirer Takeda.
Amid a spate of merger and acquisition activity in the life sciences space, in March 2018 came the news that Japan-based Takeda was considering plans to acquire biopharma company Shire.
Allergan had also put its hat in the ring for Shire, but in April, announced it wouldn’t move forward with a deal.
Takeda had its eyes on the prize—more than eight months and a series of revised proposals later, Takeda’s £46 billion ($59 billion) acquisition of Shire was approved by both sets of shareholders.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Shire Pharmaceuticals, Takeda, M&A, big data, statistics, patent prosecution, generic, brand, IP counsel, law firms, network, diversity, millennials